FDA Approves Xofigo for Advanced Prostate Cancer (06-17-2013)
The U.S. Food and Drug Administration (FDA) has approved Xofigo® (radium Ra 223 dichloride) to treat men with metastatic, hormone-refractory prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread... Continue Reading
Genomic Testing May Reduce Medical Costs for Colon Cancer (06-14-2013)
Use of the Oncotype DX® colon cancer test to guide treatment decisions may reduce medical costs and improve patient well-being. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO).
The Oncotype... Continue Reading
Immunotherapy Combination Promising for Metastatic Melanoma (06-14-2013)
For people with metastatic melanoma, treatment with a combination of Yervoy® (ipilimumab) and Leukine® (sargramostim; GM-CSF) may result in better overall survival than treatment with Yervoy alone. These results, from a Phase II clinical trial, were... Continue Reading
Maintenance Therapy with Votrient Provides Benefit in Advanced Ovarian Cancer (06-13-2013)
In a Phase III clinical trial, treatment with Votrient® (pazopanib) after initial chemotherapy improved outcomes among women with advanced ovarian cancer. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology... Continue Reading
Study Compares Genomic Testing of Normal and Cancerous Prostate Tissue (06-12-2013)
The Oncotype DX® prostate cancer test—which predicts the aggressiveness of early-stage prostate cancer and may help guide treatment decisions—is more predictive of outcome when used on tumor tissue than when used on adjacent, normal prostate tissue.... Continue Reading
Standard Dose of Radiation Therapy Outperforms Higher Dose for Advanced Non-Small Cell Lung Cancer (06-12-2013)
In a phase III clinical trial, a standard dose of radiation therapy was more effective than a higher dose for the treatment of stage III non-small cell lung cancer (NSCLC). These results will be presented at the 49th Annual Meeting of the American Society... Continue Reading
SERMs Reduce Risk of Breast Cancer (06-12-2013)
Women who take selective estrogen receptor modulators (SERMs) have a 38 percent reduced risk of breast cancer for up to 10 years after diagnosis and treatment, according to the results of a meta-analysis published in The Lancet.
A majority of breast cancers... Continue Reading
Avastin Improves Outcomes for Women with Advanced Cervical Cancer (06-11-2013)
In a Phase III clinical trial, adding Avastin® (bevacizumab) to chemotherapy prolonged overall survival among women with recurrent or metastatic cervical cancer. These results were presented at the 2013 Annual Meeting of the American Society of Clinical... Continue Reading
Gene Mutations Common In African American Women with Triple-Negative or Early Onset Breast Cancer (06-11-2013)
Among African-American women with breast cancer referred for genetic counseling, one in five had an inherited mutation in at least one of the 18 genes that are linked with breast cancer susceptibility. The frequency of gene mutations was even higher in... Continue Reading
Gene Mutations Common In African American Women with Triple-Negative or Early Onset Breast Cancer (06-10-2013)
Among African-American women with breast cancer referred for genetic counseling, one in five had an inherited mutation in at least one of the 18 genes that are linked with breast cancer susceptibility. The frequency of gene mutations was even higher in... Continue Reading
Avastin Improves Outcomes for Women with Advanced Cervical Cancer (06-10-2013)
In a Phase III clinical trial, adding Avastin® (bevacizumab) to chemotherapy prolonged overall survival among women with recurrent or metastatic cervical cancer. These results were presented at the 2013 Annual Meeting of the American Society of Clinical... Continue Reading
Breast Cancer Deadlier in Women with Cosmetic Implants (06-7-2013)
Breast cancer appears to be more deadly among women with cosmetic breast implants, according to the results of a study published in the British Medical Journal—possibly because it is detected at a more advanced stage.
Approximately 200,000 women are... Continue Reading